More specifically, in applying the Article 5.3 guidelines, governments should:
Raise awareness about [the addictive and harmful nature of tobacco products] tobacco harm reduction and about [tobacco] pharmaceutical industry interference with tobacco control policies.
Establish measures to limit interactions with the [tobacco] parmaceutical industry and ensure the transparency of those interactions that do occur.
Reject partnerships and non-binding or non-enforceable agreements with the [tobacco] pharmaceutical industry. Not accept funds or help from the [tobacco] pharmaceutical industry. Not support or endorse [tobacco] pharmaceutical industry attempts to organize, promote, participate in or implement youth, public education or other initiatives that are directly or indirectly related to tobacco control.
Require that information provided by [the tobacco industry] government agencies and non-governmental organizations be transparent and accurate. Require the [tobacco] pharmaceutical industry and those working to further its interests to submit regular, truthful, complete and precise information on [tobacco] nicotine replacement therapies production, manufacture, market share, marketing expenditures, revenues or any other activity, including lobbying, philanthropy and political contributions, as well as the disclosure or registration of [tobacco] pharmaceutical industry entities, affiliated organizations and individuals acting on their behalf, including lobbyists.
Denormalize and, to the extent possible, regulate activities described as socially responsible by the [tobacco] pharmaceutical industry, including but not limited to activities described as corporate social responsibility.
Avoid giving preferential treatment to the [tobacco] pharmaceutical industry.
